These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 6223694)

  • 1. High-dose chlorozotocin in lung cancer: a Southwest Oncology Group Phase II Study.
    Haas CD; Stephens RL; Bukowski RM; Stuckey WJ; McCracken JD; Gagliano RG; Lehane DE; Pugh RP
    Cancer Treat Rep; 1983; 67(7-8):705-7. PubMed ID: 6223694
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II evaluation of chlorozotocin in patients with non-small cell carcinoma of the lung.
    Casper ES; Gralla RJ
    Cancer Treat Rep; 1979 Apr; 63(4):549-50. PubMed ID: 156068
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II evaluation of chlorozotocin in advanced bronchogenic carcinoma.
    Creagan ET; Eagan RT; Fleming TR; Frytak S; Kvols LK; Ingle JN
    Cancer Treat Rep; 1979; 63(11-12):2105-6. PubMed ID: 230898
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II study of 5-FU, doxorubicin, and mitomycin (FAM) and chlorozotocin in advanced measureable pancreatic cancer.
    Smith FP; Rustgi VK; Schertz G; Woolley PV; Schein PS
    Cancer Treat Rep; 1982 Dec; 66(12):2095-6. PubMed ID: 6215982
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II evaluation of chlorozotocin in patients with renal cell carcinoma.
    Gralla RJ; Yagoda A
    Cancer Treat Rep; 1979 Jun; 63(6):1007-8. PubMed ID: 157222
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase II study of cisplatin, maytansine, and chlorozotocin in small cell lung carcinoma (EST 2578).
    Creech RH; Stanley K; Vogl SE; Ettinger DS; Bonomi PD; Salazar O
    Cancer Treat Rep; 1982 Jun; 66(6):1417-9. PubMed ID: 6282460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of chlorozotocin in non-small cell carcinoma of the lung.
    Cornell CJ; Hoth D; Pajak TF
    Cancer Treat Rep; 1981; 65(7-8):734-5. PubMed ID: 6454488
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II study of chlorozotocin in the treatment of advanced colorectal cancer.
    Lawton JO; Giles GR; Hall J; MacAdam A; Hall R; Matheson T; Bird G
    Cancer Treat Rep; 1981; 65(1-2):13-15. PubMed ID: 6452945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I evaluation of chlorozotocin: single dose every six weeks.
    Taylor S; Belt RJ; Haas CD; Stephens RL; Hoogstraten B
    Cancer; 1980 Dec; 46(11):2365-8. PubMed ID: 6449279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholestatic jaundice associated with chlorozotocin.
    Belt RJ; McGregor D; Haas CD; Bhatia PS
    Cancer Treat Rep; 1980; 64(12):1235-9. PubMed ID: 6451288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of chlorozotocin in advanced breast cancer.
    Edmonson JH; Green SJ; Ingle JN; Ahmann DL; Disel HF; Creagan ET
    Cancer Treat Rep; 1981; 65(5-6):537-8. PubMed ID: 6453648
    [No Abstract]   [Full Text] [Related]  

  • 12. Preclinical and clinical studies on chlorozotocin, a new nitrosourea with decreased bone marrow toxicity.
    Macdonald JS; Hoth D; Schein PS
    Recent Results Cancer Res; 1980; 70():83-9. PubMed ID: 6444466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II evaluation of chlorozotocin in refractory multiple myeloma.
    Forman WB; Cohen HJ; Bartolucci AA; Manning G
    Cancer Treat Rep; 1984 Nov; 68(11):1409-10. PubMed ID: 6238673
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase II study of maytansine and chlorozotocin in patients with disseminated malignant melanoma.
    Ahmann DL; Frytak S; Kvols LK; Hahn RG; Edmonson JH; Bisel HF; Creagan ET
    Cancer Treat Rep; 1980; 64(4-5):721-3. PubMed ID: 6448689
    [No Abstract]   [Full Text] [Related]  

  • 15. Chlorozotocin: phase II evaluation in patients with advanced sarcomas.
    Sordillo PP; Magill GB; Gralla RJ
    Cancer Treat Rep; 1981; 65(5-6):513-4. PubMed ID: 6453647
    [No Abstract]   [Full Text] [Related]  

  • 16. Chlorozotocin: phase II evaluation in patients with myeloma.
    Cornell CJ; Pajak TF; McIntyre OR
    Cancer Treat Rep; 1984 Apr; 68(4):685-6. PubMed ID: 6231990
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II study of chlorozotocin in leukemia and other hematologic malignancies.
    Pavlovsky S; Woolley PV; Garay G; Scaglione C; Hoth D; Schein PS
    Cancer Treat Rep; 1981; 65(11-12):1109-11. PubMed ID: 6457686
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase I evaluation of chlorozotocin (NSC-178248): weekly schedule.
    Moriconi WJ; Taylor S; Slavik M; Belt RJ; Haas CD; Hoogstraten B
    Invest New Drugs; 1985; 3(1):57-62. PubMed ID: 3157661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of cisplatin, 5-fluorouracil, and leucovorin augmented by vinorelbine (Navelbine) for advanced non-small cell lung cancer: rationale and study design.
    Vokes EE; Drinkard LC; Samuels BL; Hoffman PC; Watson S; Bitran JD; Haraf DJ; Ferguson MF; Golomb HM
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):79-83; discussion 83-4. PubMed ID: 7973772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of chlorozotocin in metastatic malignant melanoma.
    Hoth DF; Schein PS; Winokur S; Woolley PV; Robichaud K; Binder RB; Smith FP
    Cancer; 1980 Oct; 46(7):1544-7. PubMed ID: 6448088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.